SCHEMBL23216136

SCHEMBL23216136

Oc1cc(C2CC2)c(Cl)cc1Br

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.36
KDM1B Q8NB78 3/20 0.36
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
DRD1 P21728 4/20 0.32
DRD2 P14416 3/20 0.32
TSHR P16473 2/20 0.32
GAA P10253 1/20 0.32
AGTR1 P30556 1/20 0.32
ALOX15 P16050 1/20 0.31
DRD4 P21917 1/20 0.31
DRD5 P21918 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16736883 0.81 HTR2C (0.35) HTR2CDRD1DRD2TSHRHSD17B10
SCHEMBL16736586 0.76 CYP3A4 (0.37) HTR2CHTR2BDRD1DRD2ALOX15
SCHEMBL29663733 0.73 HSD17B10 (0.55) TSHRALOX15HSD17B10
SCHEMBL11595609 0.73 HSD17B10 (0.55) TSHRALOX15HSD17B10
SCHEMBL16736752 0.72 NUDT1 (0.33) KDM1AHTR2AHTR2CHTR2BDRD1
SCHEMBL22560913 0.72 TSHR (0.34) TSHRGAAAGTR1HSD17B10
SCHEMBL16117971 0.72 HSD17B10 (0.42) TSHRGAAAGTR1ALOX15HSD17B10
SCHEMBL24252339 0.72 HTR2C (0.51) HTR2AHTR2CHTR2B
SCHEMBL8640677 0.71 TSHR (0.52) TSHRALOX15HSD17B10
SCHEMBL5271664 0.70 KDM1A (0.36) KDM1AKDM1BTSHRALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
EP-4041229-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114727991-A Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-08 CN disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 KDM1A 151/4885KDM1B 152/4885HTR2A 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.